Renal collision tumours: three additional case reports.
Histogenesis
Histology
Kidney
Prognostic
Tumour
Journal
BMC urology
ISSN: 1471-2490
Titre abrégé: BMC Urol
Pays: England
ID NLM: 100968571
Informations de publication
Date de publication:
23 Jul 2022
23 Jul 2022
Historique:
received:
11
01
2021
accepted:
13
07
2022
entrez:
23
7
2022
pubmed:
24
7
2022
medline:
27
7
2022
Statut:
epublish
Résumé
Multiple kidney tumours are frequently seen in hereditary syndromes and familial diseases. Renal collision tumours (RCT) are characterized by the simultaneous existence of different and unrelated tumour types within the same location in the kidney, forming a single, heterogenous lesion. RCT are uncommon histological entities with distinctive features. The most frequent subtypes include clear cell renal cell carcinoma (CCRCC), papillary renal cell carcinoma (PRCC), chromophobe renal cell carcinoma (CRCC), and collecting duct carcinoma (CDC). Here, we report three sporadic cases of RCT successfully treated by nephrectomy and confirmed by histological analysis. The first case was of a 64-year-old man diagnosed with RCT composed of a stage 2 nucleolar grade 3 CCRCC and a stage 1a nucleolar grade 2 type 1 PRCC. The second case was of a 68-year-old woman diagnosed with a combined nucleolar grade 2 type 1 PRCC and an angiomyolipoma (non-assessed stage), while the third case was of a 59-year-old woman diagnosed with a combined stage 1a nucleolar grade 3 CCRCC and a stage 1b CDC. Due to the rarity of RCT, there are no standard guidelines for their management. Hence, the prognosis is considered to be associated with the most aggressive component, possibly the tumour with the highest nucleolar grade and stage. The histogenesis of RCT remains debated, and increase in knowledge regarding this can help enable the development of targeted therapies for advanced or metastatic tumours.
Sections du résumé
BACKGROUND
BACKGROUND
Multiple kidney tumours are frequently seen in hereditary syndromes and familial diseases. Renal collision tumours (RCT) are characterized by the simultaneous existence of different and unrelated tumour types within the same location in the kidney, forming a single, heterogenous lesion. RCT are uncommon histological entities with distinctive features. The most frequent subtypes include clear cell renal cell carcinoma (CCRCC), papillary renal cell carcinoma (PRCC), chromophobe renal cell carcinoma (CRCC), and collecting duct carcinoma (CDC).
CASE PRESENTATION
METHODS
Here, we report three sporadic cases of RCT successfully treated by nephrectomy and confirmed by histological analysis. The first case was of a 64-year-old man diagnosed with RCT composed of a stage 2 nucleolar grade 3 CCRCC and a stage 1a nucleolar grade 2 type 1 PRCC. The second case was of a 68-year-old woman diagnosed with a combined nucleolar grade 2 type 1 PRCC and an angiomyolipoma (non-assessed stage), while the third case was of a 59-year-old woman diagnosed with a combined stage 1a nucleolar grade 3 CCRCC and a stage 1b CDC.
CONCLUSIONS
CONCLUSIONS
Due to the rarity of RCT, there are no standard guidelines for their management. Hence, the prognosis is considered to be associated with the most aggressive component, possibly the tumour with the highest nucleolar grade and stage. The histogenesis of RCT remains debated, and increase in knowledge regarding this can help enable the development of targeted therapies for advanced or metastatic tumours.
Identifiants
pubmed: 35870918
doi: 10.1186/s12894-022-01063-y
pii: 10.1186/s12894-022-01063-y
pmc: PMC9308929
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113Informations de copyright
© 2022. The Author(s).
Références
Chin J Cancer. 2014 Jul;33(7):351-5
pubmed: 24589208
Urol Case Rep. 2020 May 30;33:101286
pubmed: 33101994
Oncology (Williston Park). 2013 Sep;27(9):893, 896, 898
pubmed: 24282987
Urology. 2015 Dec;86(6):1159-64
pubmed: 26431891
Am J Surg Pathol. 2006 Feb;30(2):141-53
pubmed: 16434887
Abdom Radiol (NY). 2017 Dec;42(12):2909-2926
pubmed: 28623377
Arch Pathol Lab Med. 2012 Apr;136(4):391-9
pubmed: 22458901
Ann Diagn Pathol. 2017 Aug;29:32-36
pubmed: 28807339
J Clin Diagn Res. 2014 Nov;8(11):FD14-6
pubmed: 25584236
Urol Int. 2004;72(4):344-8
pubmed: 15153736
Hum Pathol. 2018 Jan;71:60-64
pubmed: 28843710
Am J Clin Pathol. 2015 Nov;144(5):811-6
pubmed: 26486747
Cancer Biomark. 2010;9(1-6):461-73
pubmed: 22112490
Mod Pathol. 2001 Mar;14(3):157-63
pubmed: 11266520
Ann Pathol. 2014 Apr;34(2):164-7
pubmed: 24703033
Anticancer Res. 2005 Jan-Feb;25(1B):579-86
pubmed: 15816631
Semin Ultrasound CT MR. 2017 Feb;38(1):59-71
pubmed: 28237281
Can Urol Assoc J. 2014 Jul;8(7-8):E536-9
pubmed: 25210558
Virchows Arch. 2007 Jan;450(1):93-101
pubmed: 17124599
Urologia. 2022 May;89(2):304-306
pubmed: 33709826
Thorac Cancer. 2014 Sep;5(5):460-2
pubmed: 26763746
Int Med Case Rep J. 2012 Oct 25;5:73-7
pubmed: 23754928
Int Braz J Urol. 2020 Mar-Apr;46(2):287-293
pubmed: 32022527
Cancer Imaging. 2009 Jul 06;9:44-55
pubmed: 19602467
Pathol Res Pract. 2014 Apr;210(4):217-23
pubmed: 24447800
Pathol Res Pract. 2012 Jan 15;208(1):50-2
pubmed: 22100749
Arch Pathol Lab Med. 2003 Jan;127(1):e38-40
pubmed: 12562294
Pathologica. 2019 Mar;111(1):37-40
pubmed: 31217621
Pathol Int. 2005 Jun;55(6):360-5
pubmed: 15943794